Dr. Sumanta K. Pal on cabozantinib in papillary RCC

March 5, 2021
Urology Times staff

In the phase 2 SWOG 1500 study, cabozantinib (Cabometyx) significantly improved progression-free survival versus sunitinib (Sutent) in patients with metastatic papillary renal cell carcinoma.

Sumanta K. Pal, MD, FASCO, medical oncologist and assistant clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses results of the phase 2 SWOG 1500 study presented during the 2021 Genitourinary Cancers Symposium. The study showed that cabozantinib (Cabometyx) reduced the risk of disease progression or death by 40% compared with sunitinib in patients with metastatic papillary renal cell carcinoma. The median PFS with cabozantinib was 9.0 months versus 5.6 months with sunitinib (HR, 0.60; = .019). The response rates were 23% versus 4.0%, respectively (J Clin Oncol. 2021;339[suppl 6]:270. doi:10.1200/JCO.2021.39.6_suppl.270).